Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPancOne: Peri-Operative mFFX in Resectable Pancreatic Cancer
NCT04472910Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Aug 2020
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by University Health Network. Started Aug 2020; status: active, not recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04472910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472910.